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Activity in vitro of 22 antimicrobial agents against clinical 
isolates of Listeria monocytogenes 
CIin Microb Inzct 1996; 2: 63-64 
Although Listeria spp. show susceptibility in vitro to 
several classes of antibiotics [I-31, the treatment of 
severe listeriosis may be difficult and require the 
combination of a cell-wall-active antibiotic (ampicillin 
or vanconiycin) and an aminoglycoside [4]. The search 
for alternative regimens for the treatment of listeriosis 
is justified for several reasons: the primary resistance of 
Listeria spp. to cephalosporins, the occurrence of allerhy 
to p-lactam antibiotics, the toxicity of vanconiycin and 
dilution method on Mueller-Hinton agar (Oxoid Ltd, 
Basingstoke, UK) was used for susceptibility testing, 
following the National Conimittee for Clinical Labora- 
tory Standards, USA (NCCLS) instructions 161, with a 
find inoculuni of 10'' CFU per spot, delivered with 
a multipoint inoculator (Steers replicator). Control 
strains of Staphylococcus anreus (ATCC 2921 3) and 
Enteuococeiisfaecalics (ATCC: 29222) of known antibiotic 
susceptibility patterns were simultaneously tested. MIC 
results were interpreted according to NCCLS break- 
points, where these have been defined. In other cases, 
the following breakpoints (mg/L) were used: mero- 
peneni, 5 4 susceptible, 8 intermediate, 216 resistant; 
aniinoglycosides, frequent therapeutic failure and a 
recent report of transferable plasmid-mediated anti- 
biotic resistance [5]. 
We have evaluated the activity in vitro of 22 
and roxithroinycin, 52 susceptible, 4 intermediate, s_ 8 
resistant. 
The percentages of susceptible, intermediate and 
resistant strains and the MICs(1 arid MIC:o(, are reported 
antimicrobial agents, including newer cephalosporins, 
quinolones and niacrolides against 49 clinical strains of 
Listerid nionocytogcnes recovered from different patients 
between 1986 and 1993. The origin of these isolates 
was human blood (26), cerebrospinal fluid (12) and 
other noriiially sterile fluids (1 1). 
The 22 antimicrobial agents tested (Table 1) were 
obtained from their respective manufacturers. An agar 
Table 1 Activity in vitro of antiniicrobial agents against 
Listevia wi on u q ~ t u p n e s  
Antiinic-robial Kange MICjo MICgo %S % I  %R 
Penicillin 11.25-1 0.5 1 100 0 0 
Ampicillin 0.5-1 1 1 100 0 0 
Anmxicillin / 
clavulaiute 0.5-1 0.5 1 100 0 0 
Ccfonicid 16-32 32 32 0 12 88 
Ceiotaximc 16-2128 64 128 0 20 80 
in Table 1. All our strains were uniformly susceptible 
to penicillin, ampicillin, amoxicillin-clavulanate, new 
macrolides, vancomycin, teicoplanin, gentaniciii, tetra- 
cycline, co-trimoxazole, ciprofloxacin, imipenem and 
meropeneni, and were uniformly resistant to old and 
new cephalosporins. 
Classic cephalosporins are regularly inactive against 
L. rnonocytoxenes [I ,2,7,8]. Studies of the new cephalo- 
sporins of third and fourth generations, also show that 
no further improvement of thest. agents against Listevia 
spp. can be expected. Clarithromycin was the most 
active of the macrolides studied (MICyo 0.25 nig/L). 
Despite the good activity of the new niacrolides in 
vitro, the bacteriostatic nature of'these agents and their 
poor distribution in the brain arid central nervous 
system place them in the second line in the treatment 
of human listeriosis. Ciprofloxacin was the most active 
of the quinolones tested against all our isolates of L. 
~ e i p o d o x ~ n ~ c  32- 2128 12x >128 o o i i jo monocytugerzes (MICyo 1 nig/L). However, the liinited 
Cefuroxniie 32- 8128 64 128 0 0 100 cerebrospinal fluid diffusion of ciprofloxacin, and the 
Erythl-olllycln ')-"-' ().' 89 l1 'j limited clinical experience in listeriosis suggest that 
Clarithromycin ~0.06-0.25 50.06 0.25 100 O 0 
Kosith~-oiiiycin 0.25-2 I 10o L. m o n o c y t o p m  infections. Other newer fluoro- 
Vancomycin 0.5-1 1.5 1 100 o 0 quinolones, including fleroxacin, loniefloxacin and 
Tcicoplanin ~4-8 5 4  5 4  100 0 0 ofloxacin, have lower activity against L. moriocytopws 
Ciprofloxacin 0.2.5-1 1 loO (MICgo ranging from 4 to 8 mg/L) [l]. Sparfloxacin, 
Ofloxaciii 2-8 2 4 54 43 3 not included in our study, b a s  beeu tested again5t 
Fl r roxmn 2-8 4 8 6 71 23 
Lomeflosaci I I  2-8 4 8 63 34 L. motiocytogenes in another investigation [9] with good 
Iiiiipenetn 0.12-0.5 0.25 0.5 ioo o 0 results in vitro (MICy0 0.25 nig/L). Finally, co- 
achieves good central nervous system penetration. Gentaiiiicin 0.12-1 ( 1 5  
Tetracycline 0.5-4 1 4 100 0 0 Limited clinical experience shows co-trimoxazole to be 
Co-trinioxazole <0.5/9.5 c0.5/9.5 <0.5/9..5 100 0 0 
a viable alternative in the treatment and prophylaxis of 
S =susceptible; I =internicdiate; K=rcsistant. L. rnonocytoptes infections [8,10]. 
Azithromycin 1-2 - 3 2 100 0 , 0 ciprofloxacin is not a likely choice for the treatment of 
Mei-opcnem 50.06-0.5 0.12 0.2.5 100 0 0 trinioxazole showed a MIC90 of <().()6 mg/L 2nd 
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Multiresistant strain of Listeria monocytogenes in Greece 
Clin Microb Infect 1996; 2: 64-65 
In 1990 two reports of multiply-resistant Li5teria 
monocytogenes strains and one report of L.  rnonocytogenes 
strains resistant to erythromycin or tetracycline were 
published in France [1,2] and the UK [3] respectively. 
In one of the multiresistant strains isolated in France [2] 
a 37-kb plasmid was found to be responsible for the 
resistance to the antibiotics. Genetic characterization of 
plasmid-encoded multiple antibiotic resistance in 
another L. rnonocytogenes strain causing endocarditis 
revealed that the resistance determinants were located 
on a 39-kb plasmid [4]. 
In our laboratory, we perform antibacterial 
susceptibility tests by the disk diffusion method on 
Mueller-Hinton agar (Oxoid), on all listerial strains that 
we isolate from human, food and environmental 
sources. The zone diameters round each disk are 
interpreted on the basis of guidelines published by the 
National Committee for Clinical Laboratory Standards 
(NCCLS) [5]. Until 1995, all L. monocytogener isolates 
were susceptible, or intermediately susceptible, to 
gentamicin, rifampicin, co-trimoxazole, amikacin, 
tobramycin, tetracycline, erythromycin, vancomycin, 
cefalothin, norfloxacin, ampicillin, chloramphenicol, 
penicillin and ampicillidclavulanic acid. During 1995, 
a L. monocytogenes strain was isolated from the feces of 
a 9-month-old patient who suffered from diarrhea. 
This isolate was identified with the API Listeria kit 
(bioMerieux, France). It was hemolytic and agglutin- 
ated with both Listeria 0 polyvalent antiserum and 
Listeria 0 antiserum type 1 (Difco Laboratories, 
Detroit, Michigan). When checked by the disk-agar 
diffusion test, it was found to be resistant to gentamicin, 
tobramycin, tetracycline, erythomycin, chloramphen- 
icol, amikacin and streptomycin. Minimal inhibitory 
concentrations (MICs) were determined as outlined 
in the guidelines of the NCCLS [6], and were as 
follows: gentamicin 3 6 pg/mL, tobramycin > 8 pg/mL, 
tetracycline > 8 pg/mL, erythromycin > 4 pg/mL, 
chloramphenicol > 16 pg/mL, amikacin >32 pg/mL, 
streptomycin > 1000 pg/mL. We isolated plasmid DNA 
from this strain by the alkaline lysis method [7], and 
observed a single plasmid of approximately 37 kb. 
It was thought that L. monocytogenes was always 
susceptible to a number of antibiotics, and there was no 
need for a susceptibility test. The finding of a resistant 
isolate in Greece is important, paralleling discoveries of 
resistance in other European countries, because genta- 
micin is given in combination with ampicillin as first- 
choice treatment of human infections due to L .  
monocytogenes and erythromycin is recommended as an 
alternative in pregnancy and erythromycin or tetra- 
cycline in cases of penicillin allergy. For this reason, 
susceptibility testing is necessary in all cases of human 
listeriosis. 
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